Developing treatments for the diseases that are hardest to treat

 

We wholly own a platform with the potential for treating cancer and selecting patients who would likely benefit from the treatment. Endocyte technology is in mid-stage clinical trials.

PROGRAM TRIAL DESIGN INDICATION PRECLINICAL SAFETY / PROOF
OF CONCEPT
PHASE 2/3 PARTNERS
Radioligand Therapy (RLT)
177Lu-PSMA-617 177Lu-PSMA-617 + BSC/SC vs BSC/SC(1) mCRPC
VISION Trial: Phase 3
Q2 2018
177Lu-PSMA-617 177Lu-PSMA-617
vs. Cabazitaxel
mCRPC
Phase 2 currently enrolling
225Ac-PSMA-617 Single arm mCRPC 1H 2018
CAR T (Fluorescein CAR T-Cell, Adapter Controlled)
FITC CAR T + FITC-Folate CAM Single arm Osteosarcoma 4Q 2018
FITC CAR T + FITC-CAMs (various targets) TBD